Respiratory failure & ventilation
High-Dose Steroids for Nonresolving Acute Respiratory Distress Syndrome in Critically Ill COVID-19 Patients Treated With Dexamethasone: A Multicenter Cohort Study*
Authors' conclusion
In critically ill COVID-19 patients with nonresolving ARDS, HDCT result in a higher 90-day mortality.
Study context
- Population
- Critically ill COVID-19 patients with nonresolving acute respiratory distress syndrome (ARDS) previously treated with dexamethasone, 11 ICUs of Great Paris area, September 2020 to February 2021
- Participants
- 383 patients
- Exposure
- High-dose corticosteroids vs no high-dose corticosteroids
- High doses of corticosteroids (HDCT)n = 59
- No HDCTn = 324reference
- Outcome
- Mortality
- Follow-up
- 90 days
Methodological detailsmulticentre, overlap weighting propensity score
- Multicentre
- Overlap weighting propensity score
Main finding
As reported in the abstract
day 90
HDCT vs no HDCTEstimate (95% CI)P value
Unadjusted
HR 1.60(1.04–2.47)
P = 0.033Overlap weighting
aHR 1.65(1.03–2.63)
P = 0.036Observational data: associations, not effects.
Safety
| Outcome | Adjusted cause-specific HR (95% CI) | P value | |
|---|---|---|---|
| VAP | 0.42 (0.15–1.16) | P = 0.09 | |
| 0.10.31310Adjusted cause-specific hazard ratio (log scale) |
Original publication
High-Dose Steroids for Nonresolving Acute Respiratory Distress Syndrome in Critically Ill COVID-19 Patients Treated With Dexamethasone: A Multicenter Cohort Study*. Crit Care Med. Published 18 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →